Loading…
Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein
Pseuodotyped particles have significant importance and use in virology as tools for studying the biology of highly pathogenic viruses in a lower biosafety environment. The biological, chemical, and serological studies of the recently emerged SARS-CoV-2 will be greatly aided by the development and op...
Saved in:
Published in: | Scientific reports 2020-11, Vol.10 (1), p.19076-19076, Article 19076 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3 |
container_end_page | 19076 |
container_issue | 1 |
container_start_page | 19076 |
container_title | Scientific reports |
container_volume | 10 |
creator | Tandon, Ritesh Mitra, Dipanwita Sharma, Poonam McCandless, Martin G. Stray, Stephen J. Bates, John T. Marshall, Gailen D. |
description | Pseuodotyped particles have significant importance and use in virology as tools for studying the biology of highly pathogenic viruses in a lower biosafety environment. The biological, chemical, and serological studies of the recently emerged SARS-CoV-2 will be greatly aided by the development and optimization of a suitable pseudotyping system. Here, we pseudotyped the SARS-CoV-2 Spike glycoprotein (SPG) on a traditional retroviral (MMLV) as well as a third generation lentiviral (pLV) vector and tested the transduction efficiency in several mammalian cell lines expressing SARS-CoV-2 receptor hACE2. While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) efficiently, it could not pseudotype the full-length SPG. In contrast, pLV pseudotyped both glycoproteins efficiently; however, much higher titers of pLV-G particles were produced. Among all the tested mammalian cells, 293Ts expressing hACE2 were most efficiently transduced using the pLV-S system. The pLV-S particles were efficiently neutralized by diluted serum (>:640) from recently recovered COVID-19 patients who showed high SARS-CoV-2 specific IgM and IgG levels. In summary, pLV-S pseudotyped virus provides a valid screening tool for the presence of anti SARS-CoV-2 specific neutralizing antibodies in convalescent patient serum. |
doi_str_mv | 10.1038/s41598-020-76135-w |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7645753</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2458039211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEolXpC7BAltiwCfg3jjdI1aj8SJUq0cLWcpybqUvGDrYzo-E5eGA8TGkHFvXGls93z71Xp6peEvyWYNa-S5wI1daY4lo2hIl686Q6ppiLmjJKnx68j6rTlG5xOYIqTtTz6ogxIrgg_Lj6dT4MYLNbA0o2AnjnlygM6Orsy1W9CN9qijzMOZrR_dxJxmfXhd5BQs6jyWQHPqMEcV6hOe2IsXy4tYtzKnLMzo6FnRLMfcjbCXq0cfnm0D9N7jug5bi1YYohg_MvqmeDGROc3t0n1dcP59eLT_XF5cfPi7OL2nLJc006OlDT2h56IRSWHLhVikCPDR9U01AJgyDQYUNk14HprRSE0FZZ1oFsLTup3u99p7lbQW_L5GVRPUW3MnGrg3H6X8W7G70May0bLqRgxeDNnUEMP2ZIWa9csjCOxkOYk6ZctJgpSkhBX_-H3oY5-rJeoWSJAzeNKBTdUzaGlCIM98MQrHe5633uuuSu_-SuN6Xo1eEa9yV_Uy4A2wOpSH4J8aH3I7a_AaRuvNI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471540665</pqid></control><display><type>article</type><title>Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Free Full-Text Journals in Chemistry</source><source>Coronavirus Research Database</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Tandon, Ritesh ; Mitra, Dipanwita ; Sharma, Poonam ; McCandless, Martin G. ; Stray, Stephen J. ; Bates, John T. ; Marshall, Gailen D.</creator><creatorcontrib>Tandon, Ritesh ; Mitra, Dipanwita ; Sharma, Poonam ; McCandless, Martin G. ; Stray, Stephen J. ; Bates, John T. ; Marshall, Gailen D.</creatorcontrib><description>Pseuodotyped particles have significant importance and use in virology as tools for studying the biology of highly pathogenic viruses in a lower biosafety environment. The biological, chemical, and serological studies of the recently emerged SARS-CoV-2 will be greatly aided by the development and optimization of a suitable pseudotyping system. Here, we pseudotyped the SARS-CoV-2 Spike glycoprotein (SPG) on a traditional retroviral (MMLV) as well as a third generation lentiviral (pLV) vector and tested the transduction efficiency in several mammalian cell lines expressing SARS-CoV-2 receptor hACE2. While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) efficiently, it could not pseudotype the full-length SPG. In contrast, pLV pseudotyped both glycoproteins efficiently; however, much higher titers of pLV-G particles were produced. Among all the tested mammalian cells, 293Ts expressing hACE2 were most efficiently transduced using the pLV-S system. The pLV-S particles were efficiently neutralized by diluted serum (>:640) from recently recovered COVID-19 patients who showed high SARS-CoV-2 specific IgM and IgG levels. In summary, pLV-S pseudotyped virus provides a valid screening tool for the presence of anti SARS-CoV-2 specific neutralizing antibodies in convalescent patient serum.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-76135-w</identifier><identifier>PMID: 33154514</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/326 ; 631/326/596 ; 692/308/2778 ; Animals ; Antibodies, Neutralizing - blood ; Antibodies, Neutralizing - immunology ; Antibodies, Viral - blood ; Antibodies, Viral - immunology ; Betacoronavirus - immunology ; Cell Line ; Cell lines ; COVID-19 ; Genetic Vectors - genetics ; Glycoproteins ; Humanities and Social Sciences ; Humans ; Immunoglobulin G ; Immunoglobulin M ; Lentivirus - genetics ; Mammalian cells ; multidisciplinary ; SARS-CoV-2 ; Science ; Science (multidisciplinary) ; Serologic Tests - methods ; Severe acute respiratory syndrome coronavirus 2 ; Spike glycoprotein ; Spike Glycoprotein, Coronavirus - genetics ; Spike Glycoprotein, Coronavirus - immunology ; Stomatitis ; Transduction, Genetic</subject><ispartof>Scientific reports, 2020-11, Vol.10 (1), p.19076-19076, Article 19076</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3</citedby><cites>FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2471540665/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2471540665?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33154514$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tandon, Ritesh</creatorcontrib><creatorcontrib>Mitra, Dipanwita</creatorcontrib><creatorcontrib>Sharma, Poonam</creatorcontrib><creatorcontrib>McCandless, Martin G.</creatorcontrib><creatorcontrib>Stray, Stephen J.</creatorcontrib><creatorcontrib>Bates, John T.</creatorcontrib><creatorcontrib>Marshall, Gailen D.</creatorcontrib><title>Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Pseuodotyped particles have significant importance and use in virology as tools for studying the biology of highly pathogenic viruses in a lower biosafety environment. The biological, chemical, and serological studies of the recently emerged SARS-CoV-2 will be greatly aided by the development and optimization of a suitable pseudotyping system. Here, we pseudotyped the SARS-CoV-2 Spike glycoprotein (SPG) on a traditional retroviral (MMLV) as well as a third generation lentiviral (pLV) vector and tested the transduction efficiency in several mammalian cell lines expressing SARS-CoV-2 receptor hACE2. While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) efficiently, it could not pseudotype the full-length SPG. In contrast, pLV pseudotyped both glycoproteins efficiently; however, much higher titers of pLV-G particles were produced. Among all the tested mammalian cells, 293Ts expressing hACE2 were most efficiently transduced using the pLV-S system. The pLV-S particles were efficiently neutralized by diluted serum (>:640) from recently recovered COVID-19 patients who showed high SARS-CoV-2 specific IgM and IgG levels. In summary, pLV-S pseudotyped virus provides a valid screening tool for the presence of anti SARS-CoV-2 specific neutralizing antibodies in convalescent patient serum.</description><subject>631/326</subject><subject>631/326/596</subject><subject>692/308/2778</subject><subject>Animals</subject><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Antibodies, Viral - blood</subject><subject>Antibodies, Viral - immunology</subject><subject>Betacoronavirus - immunology</subject><subject>Cell Line</subject><subject>Cell lines</subject><subject>COVID-19</subject><subject>Genetic Vectors - genetics</subject><subject>Glycoproteins</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin M</subject><subject>Lentivirus - genetics</subject><subject>Mammalian cells</subject><subject>multidisciplinary</subject><subject>SARS-CoV-2</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Serologic Tests - methods</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike glycoprotein</subject><subject>Spike Glycoprotein, Coronavirus - genetics</subject><subject>Spike Glycoprotein, Coronavirus - immunology</subject><subject>Stomatitis</subject><subject>Transduction, Genetic</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNp9kc1u1DAUhSMEolXpC7BAltiwCfg3jjdI1aj8SJUq0cLWcpybqUvGDrYzo-E5eGA8TGkHFvXGls93z71Xp6peEvyWYNa-S5wI1daY4lo2hIl686Q6ppiLmjJKnx68j6rTlG5xOYIqTtTz6ogxIrgg_Lj6dT4MYLNbA0o2AnjnlygM6Orsy1W9CN9qijzMOZrR_dxJxmfXhd5BQs6jyWQHPqMEcV6hOe2IsXy4tYtzKnLMzo6FnRLMfcjbCXq0cfnm0D9N7jug5bi1YYohg_MvqmeDGROc3t0n1dcP59eLT_XF5cfPi7OL2nLJc006OlDT2h56IRSWHLhVikCPDR9U01AJgyDQYUNk14HprRSE0FZZ1oFsLTup3u99p7lbQW_L5GVRPUW3MnGrg3H6X8W7G70May0bLqRgxeDNnUEMP2ZIWa9csjCOxkOYk6ZctJgpSkhBX_-H3oY5-rJeoWSJAzeNKBTdUzaGlCIM98MQrHe5633uuuSu_-SuN6Xo1eEa9yV_Uy4A2wOpSH4J8aH3I7a_AaRuvNI</recordid><startdate>20201105</startdate><enddate>20201105</enddate><creator>Tandon, Ritesh</creator><creator>Mitra, Dipanwita</creator><creator>Sharma, Poonam</creator><creator>McCandless, Martin G.</creator><creator>Stray, Stephen J.</creator><creator>Bates, John T.</creator><creator>Marshall, Gailen D.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201105</creationdate><title>Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein</title><author>Tandon, Ritesh ; Mitra, Dipanwita ; Sharma, Poonam ; McCandless, Martin G. ; Stray, Stephen J. ; Bates, John T. ; Marshall, Gailen D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/326</topic><topic>631/326/596</topic><topic>692/308/2778</topic><topic>Animals</topic><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Antibodies, Viral - blood</topic><topic>Antibodies, Viral - immunology</topic><topic>Betacoronavirus - immunology</topic><topic>Cell Line</topic><topic>Cell lines</topic><topic>COVID-19</topic><topic>Genetic Vectors - genetics</topic><topic>Glycoproteins</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin M</topic><topic>Lentivirus - genetics</topic><topic>Mammalian cells</topic><topic>multidisciplinary</topic><topic>SARS-CoV-2</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Serologic Tests - methods</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike glycoprotein</topic><topic>Spike Glycoprotein, Coronavirus - genetics</topic><topic>Spike Glycoprotein, Coronavirus - immunology</topic><topic>Stomatitis</topic><topic>Transduction, Genetic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tandon, Ritesh</creatorcontrib><creatorcontrib>Mitra, Dipanwita</creatorcontrib><creatorcontrib>Sharma, Poonam</creatorcontrib><creatorcontrib>McCandless, Martin G.</creatorcontrib><creatorcontrib>Stray, Stephen J.</creatorcontrib><creatorcontrib>Bates, John T.</creatorcontrib><creatorcontrib>Marshall, Gailen D.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tandon, Ritesh</au><au>Mitra, Dipanwita</au><au>Sharma, Poonam</au><au>McCandless, Martin G.</au><au>Stray, Stephen J.</au><au>Bates, John T.</au><au>Marshall, Gailen D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-11-05</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>19076</spage><epage>19076</epage><pages>19076-19076</pages><artnum>19076</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Pseuodotyped particles have significant importance and use in virology as tools for studying the biology of highly pathogenic viruses in a lower biosafety environment. The biological, chemical, and serological studies of the recently emerged SARS-CoV-2 will be greatly aided by the development and optimization of a suitable pseudotyping system. Here, we pseudotyped the SARS-CoV-2 Spike glycoprotein (SPG) on a traditional retroviral (MMLV) as well as a third generation lentiviral (pLV) vector and tested the transduction efficiency in several mammalian cell lines expressing SARS-CoV-2 receptor hACE2. While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) efficiently, it could not pseudotype the full-length SPG. In contrast, pLV pseudotyped both glycoproteins efficiently; however, much higher titers of pLV-G particles were produced. Among all the tested mammalian cells, 293Ts expressing hACE2 were most efficiently transduced using the pLV-S system. The pLV-S particles were efficiently neutralized by diluted serum (>:640) from recently recovered COVID-19 patients who showed high SARS-CoV-2 specific IgM and IgG levels. In summary, pLV-S pseudotyped virus provides a valid screening tool for the presence of anti SARS-CoV-2 specific neutralizing antibodies in convalescent patient serum.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33154514</pmid><doi>10.1038/s41598-020-76135-w</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2045-2322 |
ispartof | Scientific reports, 2020-11, Vol.10 (1), p.19076-19076, Article 19076 |
issn | 2045-2322 2045-2322 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7645753 |
source | Open Access: PubMed Central; Publicly Available Content Database; Free Full-Text Journals in Chemistry; Coronavirus Research Database; Springer Nature - nature.com Journals - Fully Open Access |
subjects | 631/326 631/326/596 692/308/2778 Animals Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Betacoronavirus - immunology Cell Line Cell lines COVID-19 Genetic Vectors - genetics Glycoproteins Humanities and Social Sciences Humans Immunoglobulin G Immunoglobulin M Lentivirus - genetics Mammalian cells multidisciplinary SARS-CoV-2 Science Science (multidisciplinary) Serologic Tests - methods Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Spike Glycoprotein, Coronavirus - genetics Spike Glycoprotein, Coronavirus - immunology Stomatitis Transduction, Genetic |
title | Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T15%3A38%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effective%20screening%20of%20SARS-CoV-2%20neutralizing%20antibodies%20in%20patient%20serum%20using%20lentivirus%20particles%20pseudotyped%20with%20SARS-CoV-2%20spike%20glycoprotein&rft.jtitle=Scientific%20reports&rft.au=Tandon,%20Ritesh&rft.date=2020-11-05&rft.volume=10&rft.issue=1&rft.spage=19076&rft.epage=19076&rft.pages=19076-19076&rft.artnum=19076&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-76135-w&rft_dat=%3Cproquest_pubme%3E2458039211%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2471540665&rft_id=info:pmid/33154514&rfr_iscdi=true |